EGFR and non-small cell lung carcinoma: The combination of DCA, a PDK inhibitor, with first-generation EGFR-TKIs like erlotinib and gefitinib has shown promising results, and the synergistic potential of DCA with the third-generation EGFR-TKI rociletinib, alongside radiation therapy, has been demonstrated in NSCLC cell line models.